Lorlatenilib (Lorlacor)

Product detail for Lorlatenilib, INN: lorlatenilib. Therapeutic area: Oncology. This record shows all linked substances, markets, applications, presentations, and labeling artefacts.

Product ID
PROD-021
INN
lorlatenilib
Therapeutic Area
Oncology
Status
In Progress
Owner
Tomoko Ikeda
Created
2022-09-02
Last Updated
2024-04-06
Markets
10
Presentations
FormStrengthRoute
Oral solution2.5 mgTransdermal
Ophthalmic solution40 mg/0.4 mLTransdermal
Active Substances
IDNameINNCASTypeStatus
SUB-023Upadacitimabupadacitimab75138-41-9small-moleculeActive
SUB-024Semaglutidexsemaglutidex51393-36-2small-moleculeActive
Applications (3)
Application #MarketProcedure TypeStatusOwnerSubmitted
FDA-2024-0021TurkeysBLAIn ProgressSarah Chen2022-06-17
TFDA-2024-0051TurkeyNDSPendingMarcus Webb2023-06-12
FDA-2024-0081TurkeyNDACompletedJames O'Brien2023-06-06
Markets (10)
US — United StatesJP — JapanCN — ChinaES — SpainKR — South KoreaIN — IndiaSA — Saudi ArabiaPL — PolandBE — BelgiumPT — Portugal
Labeling Artefacts
IDTypeMarketVersionLanguageStatus
LBL-021IFUTurkey8.1koSubmitted
LBL-051LabelingTurkey10.3plIn Progress
LBL-081SmPCTurkey17.5itPending
LBL-111SmPCTurkey3.2frActive
LBL-141SmPCTurkey5.9zhActive